Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...
Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. Membership (fee-based) Forbes Technology Council is an invitation-only, fee-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results